#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Follicular lymphoma Small cell lung cancer extensive stage Superficial vein thrombosis Anal cancer recurrent Angiosarcoma Haemophilia B without inhibitors SAPHO syndrome Fibrosarcoma Penile squamous cell carcinoma T-cell type acute leukaemia Synovitis Fragile X syndrome Muscular dystrophy Anti-glomerular basement membrane disease Urethral valves More trials…

    Learn about Rare Diseases

    Tuberous sclerosis complex – Diagnostics Myxofibrosarcoma – Trials in Disease Niemann-Pick disease Atypical haemolytic uraemic syndrome – Diagnostics Shprintzen-Goldberg syndrome – Treatment Alagille syndrome – Basic Information Burkitt’s lymphoma – Basic Information Activated PI3 kinase delta syndrome Krabbe’s disease – Trials in Disease Osteosarcoma recurrent – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Camonsertib Avelumab 99MTC-EUK-(SO3)CY5-MAS3 Vidofludimus Calcium Fluorescein Sodium Gallium (68Ga) Psma-R2 Sodium Picosulfate Bleomycin Anv600 Levothyroxine Sodium Atomoxetine Acenocoumarol Sildenafil Ofatumumab Sacubitril Silibinin Tasipimidine Gr0015 Ezabenlimab HUPERZINE A More therapies…

    Learn about Your Condition

    Aortic valve disease Transferrin decreased Breast cancer male Pulmonary vascular disorder Tachypnoea Deafness neurosensory Perineal injury Alcoholic liver disease Chorea Glucose tolerance impaired Retroperitoneal cancer Lyme disease Pulmonary tuberculosis Restless legs syndrome Organ donor More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Breast cancer metastatic

  • Study of Disulfiram and Copper for Patients with Metastatic Breast Cancer

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • Disulfiram
    Czechia

  • Study on the Safety and Effects of Zanidatamab, Palbociclib, and Fulvestrant for Patients with Advanced or Metastatic HER2-Positive, HR-Positive Breast Cancer

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • Palbociclib
    • Fulvestrant
    • Zanidatamab
    Spain

  • Study Comparing Chemotherapy and Abemaciclib with Hormone Therapy for Patients with ER+ HER2- Metastatic Breast Cancer with Visceral Involvement

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Breast cancer metastatic
    • Breast cancer
    Investigated Drugs:
    • Abemaciclib
    • Anastrozole
    • Letrozole
    France

  • Study of BDC-1001 and Pertuzumab for Patients with HER2-Positive Metastatic Breast Cancer Previously Treated with Trastuzumab Deruxtecan

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Breast cancer metastatic
    Investigated Drugs:
    • Bdc-1001
    • Pertuzumab
    France Italy Spain

  • Study of Capivasertib and Fulvestrant for Patients with Advanced or Metastatic HR+/HER2- Breast Cancer

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Breast cancer metastatic
    • Breast cancer
    • Breast cancer female
    Investigated Drugs:
    • Capivasertib
    • Fulvestrant
    Belgium France Germany Hungary Italy Poland +1

  • Study on Trastuzumab Emtansine, Pertuzumab, and Atezolizumab for Patients with HER2-Positive Metastatic Cancer Who Benefited from Previous Treatment

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • Atezolizumab
    • Pertuzumab
    • Trastuzumab Emtansine
    Belgium France Poland Portugal Spain
Previous Page
1 … 7 8 9 10 11 … 14
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!